Literature DB >> 9843384

Mechanism of constitutive activation of the AT1 receptor: influence of the size of the agonist switch binding residue Asn(111).

Y H Feng1, S Miura, A Husain, S S Karnik.   

Abstract

The AT1 receptor is a G-protein-coupled receptor (GPCR); its activation from the basal state (R) requires an interaction between Asn111 in transmembrane helix III (TM-III) of the receptor and the Tyr4 residue of angiotensin II (Ang II). Asn111 to Gly111 mutation (N111G) results in constitutive activation of the AT1 receptor (Noda et al. (1996) Biochemistry, 35, 16435-16442). We show here that replacement of the AT1 receptors TM-III with a topologically identical 16-residue segment (Cys101-Val116) from the AT2 receptor induces constitutive activity, although Asn111 is preserved in the resulting chimera, CR18. Effects of CR18 and N111G mutations are neither additive nor synergistic. The conformation(s) induced in either mutant mimics the partially activated state (R'), and transition to the fully activated R conformation in both no longer requires the Tyr4 of Ang II. Both the R state of the receptor and the Tyr4 Ang II dependence of receptor activation can be reinstated by introduction of a larger sized Phe side chain at the 111 position in CR18, suggesting that the CR18 mutation generated an effect similar to the reduction of side chain size in the N111G mutation. Consistently in the native AT1 receptor, R' conformation is generated by replacement with residues smaller but not larger than the Asn111. However, size substitution of several other TM-III residues in both receptors did not affect transitions between R, R', and R states. Thus, the property responsible for Asn111 function as a conformational switch is neither polarity nor hydrogen bonding potential but the side chain size. We conclude that the fundamental mechanism responsible for constitutive activation of the AT1 receptor is to increase the entropy of the key agonist-switch binding residue, Asn111. As a result, the normally agonist-dependent R --> R' transition occurs spontaneously. This mechanism may be applicable to many other GPCRs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9843384     DOI: 10.1021/bi980863t

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  25 in total

1.  Systematic identification of mutations that constitutively activate the angiotensin II type 1A receptor by screening a randomly mutated cDNA library with an original pharmacological bioassay.

Authors:  C Parnot; S Bardin; S Miserey-Lenkei; D Guedin; P Corvol; E Clauser
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

2.  Gbeta gamma -independent constitutive association of Galpha s with SHP-1 and angiotensin II receptor AT2 is essential in AT2-mediated ITIM-independent activation of SHP-1.

Authors:  Ying-Hong Feng; Yan Sun; Janice G Douglas
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-09       Impact factor: 11.205

Review 3.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

4.  Ligand-specific conformation of extracellular loop-2 in the angiotensin II type 1 receptor.

Authors:  Hamiyet Unal; Rajaganapathi Jagannathan; Manjunatha B Bhat; Sadashiva S Karnik
Journal:  J Biol Chem       Date:  2010-03-18       Impact factor: 5.157

5.  Angiotensin II activates AMPK for execution of apoptosis through energy-dependent and -independent mechanisms.

Authors:  Regina M Day; Young H Lee; Li Han; Yong-Chul Kim; Ying-Hong Feng
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-08-19       Impact factor: 5.464

6.  Critical hydrogen bond formation for activation of the angiotensin II type 1 receptor.

Authors:  Jérôme Cabana; Brian Holleran; Marie-Ève Beaulieu; Richard Leduc; Emanuel Escher; Gaétan Guillemette; Pierre Lavigne
Journal:  J Biol Chem       Date:  2012-12-07       Impact factor: 5.157

7.  Unique binding behavior of the recently approved angiotensin II receptor blocker azilsartan compared with that of candesartan.

Authors:  Shin-ichiro Miura; Atsutoshi Okabe; Yoshino Matsuo; Sadashiva S Karnik; Keijiro Saku
Journal:  Hypertens Res       Date:  2012-10-04       Impact factor: 3.872

8.  The fifth transmembrane domain of angiotensin II Type 1 receptor participates in the formation of the ligand-binding pocket and undergoes a counterclockwise rotation upon receptor activation.

Authors:  Ivana Domazet; Stéphane S Martin; Brian J Holleran; Marie-Eve Morin; Patrick Lacasse; Pierre Lavigne; Emanuel Escher; Richard Leduc; Gaétan Guillemette
Journal:  J Biol Chem       Date:  2009-09-22       Impact factor: 5.157

9.  Analysis of transmembrane domains 1 and 4 of the human angiotensin II AT1 receptor by cysteine-scanning mutagenesis.

Authors:  Liping Yan; Brian J Holleran; Pierre Lavigne; Emanuel Escher; Gaétan Guillemette; Richard Leduc
Journal:  J Biol Chem       Date:  2009-11-23       Impact factor: 5.157

10.  The second transmembrane domain of the human type 1 angiotensin II receptor participates in the formation of the ligand binding pocket and undergoes integral pivoting movement during the process of receptor activation.

Authors:  Ivana Domazet; Brian J Holleran; Stéphane S Martin; Pierre Lavigne; Richard Leduc; Emanuel Escher; Gaétan Guillemette
Journal:  J Biol Chem       Date:  2009-03-09       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.